Late breaking data at europcr demonstrates long-term benefits of medtronic radiofrequency renal denervation in real-world hypertensive patients

Medtronic launches new gsr-define study to expand real-world data to 5,000 patients dublin, may 18, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced new clinical data from the global symplicity registry (gsr) indicating that renal denervation (rdn) with the medtronic symplicity™ renal denervation system was associated with clinically significant and sustained blood pressure reductions in a real-world hypertensive patient population through three years. results from the prospective, single-arm, global, observational study are being presented as a late-breaking clinical trial session at the 2021 europcr annual meeting.
MDT Ratings Summary
MDT Quant Ranking